

Lamotrigine Orally Disintegrating Tablet

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Lamotrigine Orally Disintegrating Tablet (ODT) is an anti-epileptic medication used to help control certain kinds of seizures or to treat bipolar disorder. There are several immediate release formulations of this medication that can be used such as immediate-release tablets, chewable tablets, and orally disintegrating tablets. For members who cannot swallow a pill, lamotrigine chewable tablet is a viable alternative option to Lamotrigine ODT.

Definitions

"Anti-epileptics" refers to medications used to treat seizures.

"Epilepsy" is a chronic neurological disorder characterized by the tendency to have recurrent unprovoked seizures. Two or more of these seizures occurring more than 24 hours apart can be indicative of this syndrome.

"Bipolar Disorder" is a mental health condition marked by extreme mood swings that include episodes of depression (lows) and mania (highs). It is a long-term, or chronic, condition that requires ongoing management.

Medical Necessity Criteria for Initial Authorization

The Plan considers Lamotrigine ODT medically necessary when **ALL** the following criteria are met for the applicable indication listed below:

For the treatment of Seizure Disorders:

1. The member is 2 years of age or older; **AND**
2. The member has **ONE (1)** of the following diagnoses:
 - a. partial-onset seizures; **or**
 - b. primary generalized tonic-clonic (PGTC) seizures; **or**
 - c. generalized seizures of Lennox-Gastaut syndrome; **or**
 - d. absence seizures; **AND**
3. The member is unable to use or has tried and failed **BOTH** of the following:
 - a. Lamotrigine immediate-release; **and**
 - b. Lamotrigine chewable tablet; **AND**
4. Lamotrigine ODT is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; **AND**
5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

For the treatment of Bipolar Disorder:

1. The member is 18 years of age or older; **AND**
2. The member has a diagnosis of bipolar disorder; **AND**
3. The member is unable to use or has tried and failed **BOTH** of the following:
 - a. Lamotrigine immediate-release; **and**
 - b. Lamotrigine chewable tablet; **AND**
4. Lamotrigine ODT is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; **AND**

5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

For other off-label uses:

1. The member is 18 years of age or older; **AND**
2. The medication is being requested for **ONE** of the following:
 - a. acute treatment of bipolar major depression; **or**
 - b. prophylactic therapy to decrease severity and frequency of short-lasting unilateral neuralgiform headache attacks; **or**
 - c. management of symptoms associated with trigeminal neuralgia; **AND**
3. The member is unable to use or has tried and failed **BOTH** of the following:
 - a. Lamotrigine immediate-release; **and**
 - b. Lamotrigine chewable tablet; **AND**
4. Lamotrigine ODT is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; **AND**
5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

If the above prior authorization criteria is met, lamotrigine ODT will be approved for up to 12 months.

Medical Necessity Criteria for Reauthorization

Reauthorization for 12 months will be granted if the member has chart documentation demonstrating a clinical improvement in symptoms since starting the requested medication:

For the treatment of epilepsy:

1. The member has demonstrated a reduction in severity and/or frequency of seizures.

For the treatment of bipolar disorder:

1. The member's condition has improved or stabilized based upon the prescriber's assessment.

For other off-label uses:

1. The member's condition has demonstrated improvement, as validated by clinical assessment.

Experimental or Investigational / Not Medically Necessary

Lamotrigine ODT for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

References

1. Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. *Eur J Neurol*. 2019;26(6):831-849. doi:10.1111/ene.13950.
2. Bobo WV, Shelton RC. Bipolar major depression in adults: Efficacy and adverse effects of antidepressants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed July 21, 2022.
3. Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. *Cephalalgia*. 2007;27(7):824-832. doi: 10.1111/j.1468-2982.2007.01352.x
4. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. *N Engl J Med*. 2010;362(9):790-799.
5. Gloss D, Pargeon K, Pack A, et al; AAN Guideline Subcommittee. Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary: Report of the AAN Guideline Subcommittee. *Neurology*. 2021 Dec 7;97(23):1072-1081. doi: 10.1212/WNL.0000000000012944. PMID: 34873018.
6. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. *World J Biol Psychiatry*. 2010;11(2):81-109. doi:10.3109/15622970903555881
7. Guideline Development Panel for the Treatment of Depressive Disorders. Summary of the clinical practice guideline for the treatment of depression across three age cohorts. *Am Psychol*. 2022 Sep;77(6):770-780. doi: 10.1037/amp0000904. Epub 2021 Nov 29. PMID: 34843274.
8. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2018 Jul 10;91(2):74-81. doi: 10.1212/WNL.0000000000005755. Epub 2018 Jun 13. PMID: 29898971.
9. Lamictal (lamotrigine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2023.
10. Lamictal ODT (lamotrigine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2023.
11. Lamictal XR (lamotrigine) [prescribing information]. Durham, NC: GlaxoSmithKline; January 2023.

12. May A, Leone M, Afra J, et al; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. *Eur J Neurol*. 2006;13(10):1066-1077. doi: 10.1111/j.1468-1331.2006.01566.x
13. McQuaid JR, Buelo A, Capaldi V, et al. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. *Ann Intern Med*. 2022 Oct;175(10):1440-1451. doi: 10.7326/M22-1603. Epub 2022 Sep 20. PMID: 36122380.
14. Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. *Epilepsia*. 2022 Feb;63(2):316-334. doi: 10.1111/epi.17140. Epub 2021 Dec 5. PMID: 34866176.
15. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. *Eur Geriatr Med*. 2023 Aug;14(4):625-632. doi: 10.1007/s41999-023-00777-y. Epub 2023 May 31. Erratum in: *Eur Geriatr Med*. 2023 Aug;14(4):633. doi: 10.1007/s41999-023-00812-y. PMID: 37256475; PMCID: PMC10447584.
16. Piña-Garza JE, Elterman RD, Ayala R, et al. Long-Term Tolerability and Efficacy of Lamotrigine in Infants 1 to 24 Months Old. *J Child Neurol*. 2008;23(8):853-861.
17. Piña-Garza JE, Levisohn P, Gucuyener K, et al. Adjunctive Lamotrigine for Partial Seizures in Patients Aged 1 to 24 Months. *Neurology*. 2008a;70(22, pt 2):2099-2108.
18. Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed June 27, 2022.
19. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. *Pharmacopsychiatry*. 2014;47(2):43-52. doi:10.1055/s-0033-1363258.
20. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. *Acta Psychiatr Scand*. 2014;130(6):452-469. doi:10.1111/acps.12343.
21. Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. *J Clin Neurosci*. 2008;15(5):526-534. doi:10.1016/j.jocn.2006.09.006.
22. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609.

Clinical Guideline Revision / History Information

Original Date: 11/05/2020

Reviewed/Revised: 10/14/2021, 12/01/2021, 9/15/2022, 9/21/2023, 12/19/2024